A universal curative treatment for all major types of cancer is approved before 2050.

Question

Six frontier AI models put this at 4% by 23 Oct 2076. Full reasoning from every model.

WillHappen.ai · Accepted Answer

4% — the median of 6 frontier models, resolving by 2076-10-23.

Answer

Gemini (Google): 4% — Cancer is not a single disease but hundreds of distinct genomic malignancies with high clonal heterogeneity and resistance mechanisms. No single regulatory body has ever approved a pan-cancer curative therapy across diverse solid and hematologic tumors. A universal cure requires targeting a strictly ubiquitous mechanism without lethal off-target toxicity to healthy cells. Even with rapid AI drug design and mRNA platforms, clinical validation across all common types would require decades of trials.

Answer

Claude (Anthropic): 4% — Cancer biology's diversity makes one universal cure implausible even by 2050; incremental cures per subtype are far more likely. Cancer is hundreds of molecularly distinct diseases, not one target, so a single universal curative modality is biologically implausible. Current trajectory (immunotherapy, CAR-T, mRNA vaccines) is toward personalized/subtype-specific cures, not one-size-fits-all approval. Regulatory bodies like FDA approve therapies per indication, so 'universal' approval as defined would require an unprecedented paradigm shift.

Answer

GPT (OpenAI): 7% — This hinges on whether biology permits one durable, safe strategy to defeat diverse metastatic cancers, not merely improve survival. FDA/EMA would need trial-grade cures across major solid and blood cancers, including resistant metastatic disease, before 2050. Past “universal cure” claims have not translated across tumor lineages; cancer’s mutational and microenvironmental diversity is a hard base-rate constraint. I would raise this sharply if a platform showed durable, multi-histology metastatic cures in randomized phase III trials by the late 2030s.

Answer

Grok (xAI): 7% — No shared vulnerability exists that a single approved regimen could exploit across all major metastatic cancers. FDA/EMA would need to license one therapy (or fixed combo) with durable complete responses in widespread mets of lung, breast, colorectal, prostate, pancreas etc. by… Incremental gains (checkpoint, CAR-T, ADCs) have never produced pan-cancer cures; 70 years of oncology shows type-specific biology, not a common kill-switch. A 2027–2032 trial showing >70 % 5-year DFS across ≥4 solid-tumor histologies would raise the odds; nothing like that is in late-stage pipelines now.

Answer

DeepSeek (DeepSeek): 3% — Biology, not money, is the binding constraint: no single mechanism cures 200+ histologically distinct diseases. FDA approvals target one indication at a time; a pan-cancer label would need trials across dozens of tumor types, each with its own resistance biology. Base rate: after 50 years of 'war on cancer' since the 1971 Act, zero pan-cancer curative approvals; even checkpoint inhibitors help only ~20-30% of patients. Most plausible path is engineered immune cells or off-the-shelf CAR-T, but solid-tumor antigen escape and heterogeneity have blocked cures for decades.

Answer

Qwen (Alibaba): 2% — Cancer's biological heterogeneity across tissue types makes a single universal cure implausible within any foreseeable paradigm. Cancers differ in driver mutations, microenvironment, immune evasion, and metastatic biology; no known mechanism is shared universally enough to target all. Even platform approaches (mRNA, CAR-T) require per-cancer customization, which likely fails the 'universal' resolution criterion. A development that would change my mind: discovery of a single obligate dependency common to all metastatic solid tumors, analogous to how some bacteria share a…

A universal curative treatment for all major types of cancer is approved before 2050.

An FDA-approved treatment that halts or reverses cognitive decline in Alzheimer's disease is available before 2035.

The University of Oxford conducts its space medicine program as announced between November 16 and November 20, 2026.

An autonomous surgical robot performs a complete invasive human operation without human intervention before 2032.

An FDA-approved treatment that halts or reverses cognitive decline in Alzheimer's disease becomes available before 2036.